drugset / Trial / NCT01752985

Study to Evaluate the Effects of BMS-813160 on Protein Loss in the Urine of Subjects With Type 2 Diabetes and Diabetic Kidney Disease

NCT01752985

Phase 2 Terminated 319 enrolled Bristol-Myers Squibb
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine whether BMS-813160 will reduce the amount of protein loss in the urine of subjects with type 2 diabetes and diabetic kidney disease

Timeline

Start
2013-03-18
Primary completion
2015-06-30
Completion
2015-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject BMS-813160 Small molecule 150 mg Oral
Subject BMS-813160 Small molecule 300 mg Oral